openPR Logo
Press release

NSCLC Treatment Market Size, Drugs, Emerging Therapies and Companies 2032 | DelveInsight

10-28-2024 01:17 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

NSCLC Market

NSCLC Market

DelveInsight's "NSCLC Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Explore the intricate details of the NSCLC Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive NSCLC Market Forecast. Click here to stay ahead in healthcare innovation @ NSCLC Market Size- https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the NSCLC Market Report
• In October 2024:- Alliance Foundation Trials LLC- This randomized phase II design provides a fairly rapid way to determine which of two potential neoadjuvant immunotherapy regimens holds the most promise for evaluation in a subsequent phase III trial against standard of care adjuvant immunotherapy. The AFT-16 trial of neoadjuvant atezolizumab in this setting provided proof of concept for safety of the neoadjuvant approach and for outcomes that compare favorably with standard of care therapy.
• In October 2024: Amgen- A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
• In October 2024: Pfizer- The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close. Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.
• According to DelveInsight's data, about 7 out of 10 patients in the United States had metastatic NSCLC stage IIIb and IV.
• According to the research study of Serizawa et al. (2014), the stage-specific diagnosed cases were observed to be approximately 25%, 7%, 21%, and 46% for Stage I, Stage II, Stage III, And Stage IV cases of NSCLC.
• The leading NSCLC Companies such as Convalife, Tiziana Life Science Ltd, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Bristol-Myers Squibb, Akeso, RemeGen, and others.
• Promising NSCLC Therapies such as TEPMETKO (tepotinib), Romiplostim, AMG 510, and others.

Delve deep into the NSCLC Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed NSCLC Market Forecast. Click here to shape the future @ NSCLC Epidemiology Insights- https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NSCLC Overview
NSCLC stands for Non-Small Cell Lung Cancer. It is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. NSCLC is a group of lung cancers that behave in a similar way and can be treated similarly.

NSCLC Epidemiology Insights
• Total Incident cases of NSCLC patients
• Total Diagnosed cases of NSCLC patients by Stages
• Total NSCLC cases of patients by Genetic mutation/Biomarkers
• Total Treated cases of NSCLC patients by Line of Therapies
• Total Incident cases of NSCLC patients by Histology

Navigate the complexities of the NSCLC Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful NSCLC Market Forecast. Click here to get more insights @ NSCLC Treatment Market- https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NSCLC Treatment Landscape
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting. To recommend a treatment option to a patient of NSCLC, several key factors are taken into consideration, such age of the patient, previous medical history, health status, and smoking history. Along with those, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. Furthermore, biological testing of the tumor is also crucial to understand the presence of specific mutations.
The main choice of treatment for cancer, before the discovery of targeted therapies, was chemotherapy. Chemotherapy works by disrupting the way that cancer cells grow and divide. However, these drugs can also affect normal cells. Chemotherapy can be given before or after surgery for NSCLC. Some people have chemotherapy at the same time as radiotherapy-this is called chemoradiotherapy. Chemotherapy may be given to try to cure cancer or to prolong life and control symptoms (palliative care).

NSCLC Market Dynamics
The NSCLC Market Dynamics is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as AstraZeneca, Bristol-Myers-Squibb, AbbVie, Roche, Merck , Novartis, Pfizer, Takeda Pharmaceuticals, Eli lilly, Johnson & Johnson, Sanofi, GlaxoSmithKline, and others. are involved in developing drugs for NSCLC.

Unlock insights into the NSCLC Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive NSCLC Market Forecast. Click here @ NSCLC Market Drivers and Barriers- https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NSCLC Therapies and Companies
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck

NSCLC Drugs Uptake
• Telisotuzumab Vedotin by AbbVie is an antibody drug conjugate (ADC) targeting c-Met that is being investigated to treat NSCLC. Upon intravenous administration, the monoclonal antibody moiety of Telisotuzumab Vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis. It demonstrated a promising ORR along with a tolerable safety profile in a phase II trial.
• Ensartinib/X-396 (Xcovery) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Through oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors. Besides ALK, ensartinib also potently inhibits TRKA fusions, TRKC, ROS1, EphA2, and c-MET.
• SAR408701 (Sanofi) is an immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-CEACAM5 antibody-drug conjugate SAR408701, the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.

Gain a strategic edge in the NSCLC Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth NSCLC Market Forecast. Click here to lead in advancements @ NSCLC Clinical Trials Assessment- https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the NSCLC Market Report
• Coverage- 7MM
• NSCLC Companies- Convalife, Tiziana Life Science Ltd, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Bristol-Myers Squibb, Akeso, RemeGen, and others.
• NSCLC Therapies- TEPMETKO (tepotinib), Romiplostim, AMG 510, and others.
• NSCLC Market Dynamics: NSCLC Market drivers and NSCLC Market Barriers
• NSCLC Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• NSCLC Unmet Needs, KOL's views, Analyst's views, NSCLC Market Access and Reimbursement

Table of Content
1. Key Insights
2. Executive Summary of NSCLC
3. Competitive Intelligence Analysis for NSCLC
4. NSCLC: Market Overview at a Glance
5. NSCLC: Disease Background and Overview
6. Patient Journey
7. NSCLC Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. NSCLC Unmet Needs
10. Key Endpoints of NSCLC Treatment
11. NSCLC Marketed Products
12. NSCLC Emerging Therapies
13. NSCLC: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of NSCLC
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
pigment epithelial detachment market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
mouth neoplasms market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
urinary retention market- https://www.delveinsight.com/report-store/urinary-retention-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
skin neoplasm market- https://www.delveinsight.com/report-store/skin-neoplasms-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
wilms tumor market- https://www.delveinsight.com/report-store/wilms-tumor-market
Rhabdomyosarcoma market- https://www.delveinsight.com/report-store/rhabdomyosarcoma-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NSCLC Treatment Market Size, Drugs, Emerging Therapies and Companies 2032 | DelveInsight here

News-ID: 3712318 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for NSCLC

Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants. Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904 Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer. Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how
Rising Number of Cancer Patients Expands Scope for Global NSCLC Market
Non-small cell lung cancer (NSCLC) has been identified as the most common type of epithelial lung cancer. Adenocarcinomas, squamous cell carcinomas, and large cell carcinomas are the major types of NSCLC. Unlike small cell lung cancer (SCLC), NSCLC exhibits low receptivity to chemotherapy, owing to which, the need for NSCLC therapeutics has been persistently escalating in the global arena. In this research report, the global NSCLC market therapeutics has been evaluated